How Lowering Uric Acid Levels Affects Kidney Disease in Gout Patients
Author Information
Author(s): Wang Yilun MD PhD, Dalbeth Nicola MD, Terkeltaub Robert MD, Zhang Yuqing DSc, Li Xiaoxiao MS, Zeng Chao MD PhD, Lei Guanghua MD PhD, Wei Jie PhD
Primary Institution: Xiangya Hospital, Central South University, Changsha, China
Hypothesis
How does urate-lowering therapy (ULT) affect the progression of chronic kidney disease (CKD) in patients with gout and impaired kidney function?
Conclusion
Lowering serum urate levels to less than 6 mg/dL in patients with gout and CKD stage 3 does not increase the risk of severe or end-stage kidney disease.
Supporting Evidence
- The study included 14,792 patients with gout and CKD stage 3.
- The 5-year risk of severe or end-stage kidney disease was 10.32% for those achieving target urate levels.
- The adjusted hazard ratio for severe or end-stage kidney disease was 0.89.
Takeaway
This study shows that lowering uric acid levels in gout patients with kidney problems is safe and doesn't make their kidneys worse.
Methodology
This cohort study used data from a general practice database to evaluate the association between achieving target serum urate levels and CKD progression.
Potential Biases
Potential selection bias and confounding by indication may affect the results.
Limitations
Residual confounding cannot be ruled out, and the generalizability may be limited due to exclusion criteria.
Participant Demographics
Mean age was 73.1 years, with 62.3% men and 37.7% women.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI, −4.61% to −0.21%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website